Predictive modeling for body mass index based on socio-demographic, clinical-biological and anamnestic parameters in patients with severe mental disorders

Aim – to find the predictors of high BMI values among socio-demographic, clinical-biological and anamnestic parameters in patients with severe mental disorders. Materials and methods: The study collected socio-demographic, clinical-anamnestic, anthropometric and clinical-biological data of 103 patients with diagnoses within the headings F31, F32, F33, F20 to analyze their impact on the body mass index (BMI). Results: Several regression models were obtained and tested for the total sample. The best model showed an association of increased BMI with a larger number of exacerbation episodes, a diagnosis of schizophrenia, moderate severity of psychopathological symptoms (PANSS) and global clinical impression (CGI), patient age, higher levels of insulin, cholesterol, triiodthyronine (free T3), absolute lymphocyte count, and platelet-to-lymphocyte ratio (PLR). Factors influencing BMI in patients with affective pathology and schizophrenia were assessed separately. Conclusion: Models for different nosological groups partially had similar features. The common parameters were the number of exacerbation episodes, moderate severity of the disease, the patient's age, and high cholesterol. For affective patients, the age of the initial visit to a psychiatrist was another significant indicator for the BMI. For patients with schizophrenia, the indicators are the presence of cardiovascular pathology, the duration of the disease, higher levels of insulin, triglycerides, and PLR.

1. Averyanova IV. Occurrence of metabolic syndrome components in northerners. Klinicheskaya Laboratornaya Diagnostika. 2022;67(8):444-450. (In Russ.). https://doi.org/10.51620/0869-2084-2022-67-8-444-450

2. Vasilenko LM, Gorobets LN, Litvinov AV, Bulanov VS, Litvinova TA. Anthropometric and biochemical profile of patients with schizophrenia spectrum disorders and various types of eating behavior and appetite disorders. Social'naya i klinicheskaya psihiatriya. 2022;32(3):12-18. (In Russ.).

3. Gerasimchuk ES, Lutova NB, Sorokin MYu, Makarevich OV, Khobeish MA. Methods of automated linear modeling in biomedical research on the example of predicting psychiatric hospitalizations. Byulleten' medicinskoj nauki. 2024;4(36):47-61. (In Russ.). https://doi.org/10.31684/25418475-2024-4-47

4. Golenkov AV, Madyanov IV, Shmeleva SV, Petrova GD, Kamynina NN, Logachov NV. The relationship between body mass index and mental disorders in the adult population. Zdravoohranenie Rossijskoj Federacii. 2020;64(6):336-342. (In Russ.). https://doi.org/10/46563/0044-197x-2020-64-6-336-342

5. Gorobets LN, Bulanov VS, Vasilenko LM, Litvinov AV, Poliakovskaia TP. Zhurnal nevrologii i psihiatrii im. S.S. Korsakova. 2012;112(9):90-96. (In Russ.).

6. Kobyakova OS, Starodubov VI, Khalturina DA, Zykov VA, Zubkova TS, Zamyatina ES. Promising measures to reduce the mortality in Russia: an analytical review. Zdravookhranenie Rossiiskoi Federatsii. 2021;65(6):573–580. (In Russ.). https://doi.org/10.47470/0044-197x-2021-65-6-573-580

7. Kornetova EG, Galkin SA, Kornetov AN, Schastniy ED, Petkun DA, Mednova IA, Bokhan NA. Comparative study of metabolic disorders in inpatients with schizophrenia and affective disorders. Social'naya i klinicheskaya psihiatriya. 2024;34(2):5-12 (In Russ.).

8. Mazo GE, Kibitov AO. Risk management of metabolic disorders in the use of antipsychotics. V.M. Obozrenie psihiatrii i medicinskoj psihologii imeni V.M. Bekhtereva. 2016;(3):85-97. (In Russ.).

9. Perechen' poruchenij po itogam zasedaniya Soveta po strategicheskomu razvitiyu i nacional'nym proektam. №Pr-1383. [kremlin.ru]. kremlin; 2021. Available at: http://www.kremlin.ru/acts/assignments/orders/66331/print (In Russ.).

10. Frolova EB, Tsybulkin NA, Abdrahmanova AI. Metabolic syndrome as a causative factor of medical emergencies. Vestnik sovremennoj klinicheskoj mediciny. 2018;11(5):118–124. (In Russ.). https://doi.org/10.20969/VSM.2018.11(5).1180124.

11. Abou Abbas L, Salameh P, Nasser W, Nasser Z, Godin I. Obesity and symptoms of depression among adults in selected countries of the Middle East: a systematic review and meta-analysis. Clin Obes. 2015;5(1):2-11. https://doi.org/10.1111/cob.12082.

12. Annamalai A, Kosir U, Tek C. Prevalence of obesity and diabetes in patients with schizophrenia. World J Diabetes. 2017;8(8):390-396. https://doi.org/10.4239/wjd.v8.i8.390.

13. Bak M, Fransen A, Janssen J, Van Os J, Drukker M. Almost all antipsychotics result in weight gain: A meta-analysis. PLoS One. 2014;9(4):e94112. https://doi.org/10.1371/journal.pone.0094112.

14. Blasco BV, García-Jiménez J, Bodoano I, Gutiérrez-Rojas L. Obesity and depression: its prevalence and influence as a prognostic factor: a systematic review. Psychiatry Investig. 2020;17(8):715-724. https://doi.org/10.30773/pi.2020.0099.

15. Bond DJ, Andreazza AC, Hughes J, et al. Association of peripheral inflammation with body mass index and depressive relapse in bipolar disorder. Psychoneuroendocrinology. 2016;65:76-83. https://doi.org/10.1016/j.psyneuen.2015.12.012.

16. Burrows K, Stewart JL, Antonacci C, et al. Association of poorer dietary quality and higher dietary inflammation with greater symptom severity in depressed individuals with appetite loss. J Affect Disord. 2020;263:99-106. https://doi.org/10.1016/j.jad.2019.11.160.

17. Calkin C, van de Velde C, Růzicková M, Slaney C, Garnham J, Hajek T, et al. Can body mass index help predict outcome in patients with bipolar disorder? Bipolar Disord. 2009;11(6):650-6. https://doi.org/10.1111/j.1399-5618.2009.00730.x.

18. Chen J, Perera G, Shetty H, Broadbent M, Xu Y, Stewart R. Body mass index and mortality in patients with schizophrenia spectrum disorders: a cohort study in a South London catchment area. Gen Psychiatr. 2022;35(5):e100819. https://doi.org/10.1136/gpsych-2022-100819.

19. Chen X, Fan Y, Ren W, Sun M, Guan X, Xiu M, et al. Baseline BMI is associated with clinical symptom improvements in first-episode schizophrenia: a longitudinal study. Front Pharmacol. 2023;14:1264591. https://doi.org/10.3389/fphar.2023.1264591.

20. Correll CU, Detraux J, De Lepeleire J, De Hert M. Effects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder. World Psychiatry. 2015;14(2):119-36. https://doi.org/10.1002/wps.20204.

21. Feng X, Zhu J, Hua Z, et al. The prevalence and determinant of overweight and obesity among residents aged 40–69 years in high-risk regions for upper gastrointestinal cancer in southeast China. Sci Rep. 2023;13:8172. https://doi.org/10.1038/s41598-023-35477-x.

22. Fleischman A, Lurie I. Cardiovascular mortality and related risk factors among persons with schizophrenia: a review of the published literature. Public Health Rev. 2012;34:11. https://doi.org/10.1007/BF03391679.

23. Gao Z, Xiu M, Liu J, et al. Obesity, antioxidants and negative symptom improvement in first-episode schizophrenia patients treated with risperidone. Schizophr. 2023;9:17. https://doi.org/10.1038/s41537-023-00346-z.

24. Harrison RNS, Gaughran F, Murray RM, et al. Development of multivariable models to predict change in body mass index within a clinical trial population of psychotic individuals. Sci Rep. 2017;7:14738. https://doi.org/10.1038/s41598-017-15137-7.

25. Hartwig F, Bowden J, Loret de Mola C, et al. Body mass index and psychiatric disorders: a Mendelian randomization study. Sci Rep. 2016;6:32730. https://doi.org/10.1038/srep32730.

26. Heald A, Daly C, Warner-Levy JJ, et al. Weight change following diagnosis with psychosis: a retrospective cohort study in Greater Manchester, UK. Ann Gen Psychiatry. 2024;23:1. https://doi.org/10.1186/s12991-023-00485-8.

27. Kassem M, Haddad C, Daccache C, Hayek C, Hallit S, Kazour F. Factors associated with overweight and obesity in Lebanese male patients with schizophrenia. Perspect Psychiatr Care. 2021;57:1347-55. https://doi.org/10.1111/ppc.12697.

28. Kornetova EG, Kornetov AN, Mednova IA, et al. Body fat parameters, glucose and lipid profiles, and thyroid hormone levels in schizophrenia patients with or without metabolic syndrome. Diagnostics. 2020;10(9):683. https://doi.org/10.3390/diagnostics10090683.

29. Lasić D, Bevanda M, Bošnjak N, et al. Metabolic syndrome and inflammation markers in patients with schizophrenia and recurrent depressive disorder. Psychiatr Danub. 2014;26(3):214-9.

30. Leucht S, Cipriani A, Spineli L, et al. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: A multiple-treatments meta-analysis. Lancet. 2013;382(9896):951-62. https://doi.org/10.1016/S0140-6736(13)60733-3.

31. Liang J, Cai Y, Xue X, et al. Does schizophrenia itself cause obesity? Front Psychiatry. 2022;13:934384. https://doi.org/10.3389/fpsyt.2022.934384.

32. Limosin F, Gasquet I, Leguay D, et al. Body mass index and prevalence of obesity in a French cohort of patients with schizophrenia. Acta Psychiatr Scand. 2008;118(1):19-25. https://doi.org/10.1111/j.1600-0447.2008.01208.x.

33. Mansoor B, Rengasamy M, Hilton R, et al. The bidirectional relationship between body mass index and treatment outcome in adolescents with treatment-resistant depression. J Child Adolesc Psychopharmacol. 2013;23. https://doi.org/10.1089/cap.2012.0095.

34. Manu P, Khan S, Radhakrishnan R, et al. Body mass index identified as an independent predictor of psychiatric readmission. J Clin Psychiatry. 2014;75(6):e573-7. https://doi.org/10.4088/JCP.13m08795.

35. McElroy SL, Keck PE Jr. Obesity in bipolar disorder: an overview. Curr Psychiatry Rep. 2012;14(6):650-8. https://doi.org/10.1007/s11920-012-0313-8.

36. Monem RG, Okusaga OO. Repetitive transcranial magnetic stimulation: A potential treatment for obesity in patients with schizophrenia. Behav Sci (Basel). 2021;11(6):86. https://doi.org/10.3390/bs11060086.

37. Muntané G, Vázquez-Bourgon J, Sada E, et al. Polygenic risk scores enhance prediction of body mass index increase in individuals with a first episode of psychosis. Eur Psychiatry. 2023;66(1):e28. https://doi.org/10.1192/j.eurpsy.2023.9.

38. Nigatu YT, Bültmann U, Reijneveld SA. The prospective association between obesity and major depression in the general population: does single or recurrent episode matter? BMC Public Health. 2015;15:350. https://doi.org/10.1186/s12889-015-1682-9

39. Perry BI, Burgess S, Jones HJ, et al. The potential shared role of inflammation in insulin resistance and schizophrenia: A bidirectional two sample mendelian randomization study. PLoS Med. 2021;18(3):e1003455. https://doi.org/10.1371/journal.pmed.1003455

40. Perry BI., Bowker N, Burgess S, et al. Evidence for Shared Genetic Aetiology Between Schizophrenia, 2022 Cardiometabolic, and Inflammation-Related Traits: Genetic Correlation and Colocalization Analyses. Schizophr Bull Open. 2022;11;3(1):sgac001. https://doi.org/10.1093/schizbullopen/sgac001

41. Peters T, Nüllig L, Antel J, et al. The Role of Genetic Variation of BMI, Body Composition, and Fat Distribution for Mental Traits and Disorders: A Look-Up and Mendelian Randomization Study. Front Genet. 2020;11(373):1–17. https://doi.org/10.3389/fgene.2020.00373

42. Puzhko S, Aboushawareb SAE, Kudrina I, et al. Excess body weight as a predictor of response to treatment with antidepressants in patients with depressive disorder. J. Affect Disord. 2020;267:153-170. https://doi.org/10.1016/j.jad.2020.01.113

43. Ratliff JC, Palmese LB, Reutenauer EL, et al. Obese schizophrenia spectrum patients have significantly higher 10-year general cardiovascular risk and vascular ages than obese individuals without severe mental illness. Psychosomatics. 2013;54(1):67-73. https://doi.org/10.1016/j.psym.2012.03.001.

44. Rødevand L, Rahman Z, Hindley GFL, et al. Characterizing the Shared Genetic Underpinnings of Schizophrenia and Cardiovascular Disease Risk Factors. Am J Psychiatry. 2023;180(11):815-826. https://doi.org/10.1176/appi.ajp.20220660

45. Sattar A, Baig S, Naveed ur Rehman, Bashir B. Factors affecting BMI; Assessment of the effect of sociodemographic factors on BMI In the population of Ghulam Mohammad Abad Faisalabad. Professional Med J. 2013;20(6):956-964

46. Shah P, Iwata Yu, Caravaggio F, et al. Alterations in body mass index and waist-to-hip ratio in never and minimally treated patients with psychosis: A systematic review and meta-analysis, Schizophrenia Res. 2019;208:420-429. https://doi.org/10.1016/j.schres.2019.01.005

47. Strassnig M, Kotov R, Cornaccio D, et al. Twenty-year progression of body mass index in a county-wide cohort of people with schizophrenia and bipolar disorder identified at their first episode of psychosis. Bipolar Disord. 2017;19(5):336-343. https://doi.org/10.1111/bdi.12505.

48. Sugawara N, Yasui-Furukori N, Sato Y. et al. Body mass index and quality of life among outpatients with schizophrenia in Japan. BMC Psychiatry. 2013;13:108. https://doi.org/10.1186/1471-244X-13-108

49. Swinburn BA, Sacks G, Hall KD, et al. The global obesity pandemic: shaped by global drivers and local environments. Lancet. 2011;378(9793):804-14. https://doi.org/10.1016/S0140-6736(11)60813-1.

50. Teasdale SB, Ward PB, Samaras K, et al. Dietary intake of people with severe mental illness: Systematic review and meta-analysis. Br J Psychiatry. 2019;214(5):251–9. https://doi.org/10.1192/bjp.2019

51. Tseng PT, Wang HY, Cheng YS, et al. The metabolic syndrome and risk of coronary artery disease in patients with chronic schizophrenia or schizoaffective disorder in a chronic mental institute. Kaohsiung J Med Sci. 2014;30(11):579-86. https://doi.org/10.1016/j.kjms.2014.09.002.

52. Vochoskova K, McWhinney SR, Fialova M, et al. Weight and metabolic changes in early psychosis-association with daily quantification of medication exposure during the first hospitalization. Acta Psychiatr Scand. 2023;148(3):265-276. https://doi.org/10.1111/acps.13594.

53. Zaki N, Sadek H, Hewedi D, et al. Metabolic profile and indices in a sample of drug-naive patients with schizophrenia and bipolar disorder. Middle East Current Psychiatry. 2014;21(1):22-27. https://doi.org/10.1097/01.XME.0000438128.94669.57

54. Zhang J-J, Wang X-Q, Zeng Q, et al. Prevalence and associated clinical factors for overweight and obesity in young first-episode and drug-naïve Chinese patients with major depressive disorder. Front. Psychiatry. 2023;14:1278566. https://doi.org/10.3389/fpsyt.2023.1278566

55. Zhuo C, Zhang Q, Wang L, et al. Insulin Resistance/Diabetes and Schizophrenia: Potential Shared Genetic Factors and Implications for Better Management of Patients with Schizophrenia. CNS Drugs. 2024;38:33–44. https://doi.org/10.1007/s40263-023-01057-w